Fig. 1
From: Refining mutanome-based individualised immunotherapy of melanoma using artificial intelligence
Overview of malignant melanoma along with its new therapeutic targets. CTLA-4, cytotoxic T-lymphocyte associated protein-4; PD-1, programmed cell death protein 1; TCR, T cell receptor; PDL-1, programmed death ligand 1; MHC, major histocompatibility complex; DC, dendritic cell; BRAF, v-Raf murine sarcoma viral oncogene homolog B1; MEK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; RAF, rapidly activated fibrosarcoma; RAS, rat sarcoma; RTK, receptor tyrosine kinase; GTP, guanosine triphosphate; NRAS, neuroblastoma RAS viral oncogene homolog; PTEN, phosphatase and tensin homolog; TP53, tumour protein 53; BRCA, breast cancer gene; CDK, Cyclin dependent kinase